GlassScriptPhysician profile
Mohamed Osman
NPI 1750766655
$2,848.44
in general payments reported to CMS, 2019-2025
10 companies · $1,874 in 2025
The $1,874 reported for 2025 was more than what 97% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $219 · 2024: $755 · 2025: $1,874.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,387 · Travel and Lodging: $462.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,386.58 |
| Travel and Lodging | $461.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $786.47 | 2025 | General - Therapies |
| Gilead Sciences, INC. | $682.90 | 2023-2025 | Epclusa, Livdelzi |
| Abbvie INC. | $521.49 | 2023-2025 | |
| Janssen Scientific Affairs, LLC | $361.28 | 2024-2025 | Tremfya, Stelara |
| Janssen Biotech, INC. | $237.69 | 2025 | Tremfya |
| Bard Peripheral Vascular, INC. | $119.67 | 2025 | Venovo |
| Genzyme Corporation | $85.60 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.63 | 2025 | Entyvio |
| Braintree Laboratories, INC. | $19.18 | 2025 | Suflave, Sutab |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.53 | 2025 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohamed Osman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.